| Literature DB >> 30057925 |
Neetu Boodoosingh1, Rajeev Seecheran1, Saleem Varachhia1, Narine Mack1, Vinay Minocha1, Stanley Giddings2, Naveen Anand Seecheran2.
Abstract
Kawasaki disease is an acute multisystemic vasculitis occurring predominantly in children and rarely in adults, with sequelae of potentially life-threatening coronary artery aneurysms. "Incomplete" Kawasaki disease is a novel concept and considered a diagnosis of exclusion as it alludes to patients with fever lasting ⩾5 days and 2 or 3 clinical criteria without another reasonable explanation for the illness. The multidisciplinary team should be vigilant for this oligosymptomatic clinical presentation, specifically within this subgroup despite age and ethnicity, and the syndrome should be considered as a differential diagnosis in challenging cases presenting as infectious or autoimmune disease.Entities:
Keywords: South Asian; adult; incomplete Kawasaki disease; incomplete Kawasaki syndrome
Year: 2018 PMID: 30057925 PMCID: PMC6058420 DOI: 10.1177/2324709618792028
Source DB: PubMed Journal: J Investig Med High Impact Case Rep ISSN: 2324-7096
Figure 1.(a) The patient’s bilateral keratoconjunctivitis with chemosis, indicated by the black arrow. (b) The patient’s strawberry tongue glossitis with hyperplastic fungiform papillae, indicated by the black arrow. (c) The patient’s palmar desquamation with incomplete dehiscence of the epidermis and associated ichthyosis, indicated by the black arrow.
Comprehensive Laboratory Testing Including the Infectious and Immunologic Panels.
| Tests Performed | Result | Reference Range |
|---|---|---|
| Complete blood count, comprehensive metabolic panel | ||
| White cell count | 16.1 × 109/L | 4.5-11.0 × 109/L |
| Hemoglobin | 12.9 g/dL | 14.0-17.5 g/dL |
| Platelet count | 606 × 103/µL | 156-373 × 103/µL |
| Serum potassium | 4.1 µmol/L | 3.5-5.1 µmol/L |
| Serum sodium | 136 µmol/L | 135-145 µmol/L |
| Serum creatinine | 0.7 mg/dL | 0.5-1.2 mg/dL |
| Blood urea nitrogen | 10 mg/dL | 3-20 mg/dL |
| Fasting blood sugar | 80 mg/dL | 60-120 mg/dL |
| Alanine aminotransferase | 90 IU/L | 20-60 IU/L |
| Aspartate aminotransferase | 35 IU/L | 5-40 IU/L |
| Total bilirubin | 0.9 mg/dL | 0.2-1.2 mg/dL |
| Alkaline phosphatase | 120 U/L | 40-129 IU/L |
| Albumin | 3.4 g/dL | 3.5-5.5 g/dL |
| Albumin-corrected calcium | 9.6 mg/dL | 9.6-11.2 mg/dL |
| Infectious diseases panel | ||
| Erythrocyte sedimentation rate | 60 mm/h | 0-22 mm/h |
| C-reactive protein | 90 mg/dL | 0.0-1.0 mg/dL |
| Blood cultures | Negative | Positive or negative |
| Urine culture | Negative | Positive or negative |
| Stool culture | Negative | Positive or negative |
| Stool ova, cyst, and parasites | Negative | Positive or negative |
| Human immunodeficiency virus enzyme-linked immunosorbent assay | Nonreactive | Nonreactive or reactive |
| Venereal disease research laboratory test | Nonreactive | Nonreactive or reactive |
| QuantiFERON-TB GOLD (Cellestis Limited, Carnegie, Victoria, Australia) | Negative | Positive or negative |
| Hepatitis B surface antigen | Negative | Positive or negative |
| Hepatitis C immunoglobulin M (IgM) antibodies | Negative | Positive or negative |
| Hepatitis C Immunoglobulin G (IgG) antibodies | Negative | Positive or negative |
| Influenza A and B nasal swabs | Negative | Positive or negative |
| Adenoplus (Quidel Corporation, San Diego, CA) | Negative | Positive or negative |
| Echovirus antibodies (6,7,9,11, and 30) | <1:10 | <1:10 |
| Coxsackie B virus antibodies (B1-B6) | <1:10 | <1:10 |
| Dengue IgM antibodies | Negative | Positive or negative |
| Dengue IgG antibodies | Negative | Positive or negative |
| Malaria thick and thin smears | Negative | Positive or negative |
| Leptospirosis IgM antibodies | Negative | Positive or negative |
| Mycoplasma IgM antibodies | Negative | Positive or negative |
| Mycoplasma IgG antibodies | Negative | Positive or negative |
| Urine Legionella antigen | Negative | Positive or negative |
| Heterophile antibody test | Negative | Positive or negative |
| Epstein-Barr virus IgM antibodies | Negative | Positive or negative |
| Epstein–Barr virus IgG antibodies | Negative | Positive or negative |
| Cytomegalovirus IgM antibodies | Negative | Positive or negative |
| Cytomegalovirus IgG antibodies | Negative | Positive or negative |
| Stool clostridium difficile toxin A/B | Negative | Positive or negative |
| Antistreptolysin O Titer | 90 IU/mL | 0-200 IU/mL |
| Immunologic and rheumatologic panel | ||
| Antinuclear factor | Negative | Positive or negative |
| Anti–double stranded deoxyribonucleic acid antibodies | <30.0 U/mL | <30.0 U/mL (negative) |
| C3 | 190 mg/dL | 83-193 mg/dL |
| C4 | 43 mg/dL | 15-75 mg/dL |
| Anti–cyclic citrullinated peptide antibodies | <20.0 U/mL | <20.0 U/mL (negative) |
| Rheumatoid factor | Negative | Positive or negative |
| Extractable nuclear antigen panel including anti-RNP, -Ro, -La, -SCL-70, -Jo1, and –centromere | All negative | Positive or negative |
| Perinuclear anti-neutrophil cytoplasmic antibodies | 5.42 U/mL | <10.0 U/mL (negative) |
| Cytoplasmic anti-neutrophil cytoplasmic antibodies | 3.73 U/mL | < 10.0 U/mL (negative) |
| Cryoglobulin blood test | Negative | Positive or negative |
Criteria for Diagnosis of Kawasaki Disease.[8-10].
| Fever ⩾5 days and ⩾4 days of the following: |
| • Rash: diffuse maculopapular eruption, diffuse erythroderma, or erythema multiforme-like rash |
| • Conjunctivitis: bilateral bulbar conjunctival injection without exudate |
| • Cervical lymphadenopathy: usually unilateral, ⩾1.5 cm lymph node, anterior cervical triangle |
| • Extremity changes: erythema and edema of the hands and feet in acute phase, desquamation of the fingers and toes usually begin in the periungual region in subacute phase |
| • Oral changes: erythema and cracking of lips, strawberry tongue with erythema, and prominent fungiform papillae, diffuse erythema of the oropharyngeal mucosa |